Business
Faron Result of Annual General Meeting
Faron Result of Annual General Meeting.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 4092Z Faron Pharmaceuticals Oy 26 May 2016 \n\nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\n \nResult of Annual General Meeting\n \nTURKU - FINLAND 26 May 2016 - Faron Pharmaceuticals Ltd (LON: FARN) is pleased to announce that all resolutions proposed at its Annual General Meeting held today and as set out in the Company's announcement dated 4 May 2016, were duly passed by shareholders. \nCommenting on the meeting, Frank Armstrong, Chairman of Faron, said: \"We are delighted to have such support from our shareholders at the very first Annual General Meeting as a listed company. We thank our shareholders for sharing Faron´s mission of life-saving drug development. We are looking forward to making further significant progress with our innovations to develop new treatments for true unmet medical needs.\"\nFor more information, please contact:\n \nFaron Pharmaceuticals Oy\nKatja Wallenlind\nPhone +358 (50) 577 4807\nE-mail: [email protected]\n \nCairn Financial Advisers LLP, Nominated Adviser\nEmma Earl, Tony Rawlinson and Rebecca Anderson \nPhone: +44 207 148 7900\n \nPanmure Gordon (UK) Limited, Joint Broker\nFreddy Crossley, Duncan Monteith (Corporate Finance)\nTom Salvesen (Corporate Broking)\nPhone: +44 207 886 2500\n \nWhitman Howard Limited, Nominated Broker\nRanald McGregor-Smith, Francis North\nPhone: +44 207 659 1234\n \nHume Brophy, PR\nMary Clark, Eva Haas, Hollie Vile\nPhone: +44 207 862 6390\nE-mail: [email protected]\n \nAbout Faron Pharmaceuticals Ltd.\n \nFaron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome (\"ARDS\"), a rare, severe, life threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focus...